ALXO - ALX Oncology P/S Multiple

Brandmark of alxoncology.com (ALXO)

ALX Oncology Holdings (ALXO) competes for market share through safe inhibitors in combination therapy. Development relies on the success of clinical trials and external financing. The brand's high authority is confirmed by the development of efvapcept for combating tumors. The dynamics of the market cap-to-revenue ratio help assess the asset's value, with this metric currently equal to .

ALXO (ALX Oncology Holdings) Price-to-Revenue Ratio history from 07/04/2022 to 11/18/2026

ALX Oncology Holdings (ALXO) - metric breakdowns and financial figures

- market price and analyst price targets:
General company analysis:ALX Oncology Holdings, ALXO
Manufactured product of ALX Oncology Holdings Inc.

This metric is calculated as the ratio of market capitalization to annual revenue, reflecting the cost of each unit of sales. This multiple allows for an assessment of market expectations relative to the business's actual cash flows. For ALX Oncology Holdings (ALXO), during the expansion of Phase II/III clinical trials, the metric serves as an indicator of investor confidence in the future commercial success of its drugs. Analyzing the price-to-sales multiple on the GURU.Markets platform helps identify valuation deviations from the company's fundamental prospects.